Biotech Values

[DewDiligence]

PFE acquires (private) InnoPharma for $225M in cash plus contingent payments:

http://finance.yahoo.com/news/pfizer-acquire-innopharma-inc-132600185.html

Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

InnoPharma’s current portfolio includes 10 generic products approved by the United States Food and Drug Administration. The company also has a pipeline of 19 products filed with FDA and more than 30 injectable and ophthalmic products under development. The company seeks to develop novel formulations of existing drugs, including hard-to-make products, such as those that require complex manufacturing capabilities or have bio-equivalency challenges, in areas such as cancer and central nervous disorders.

…Established in 2005, InnoPharma has a comprehensive research and development facility in Piscataway, NJ. The company has developed capabilities in complex injectable delivery forms, including pens and depot injectibles, and is working to leverage this expertise to expand into new dosage forms, including oral suspensions and nasals.

These days, every generic-drug company claims to be focused on difficult-to-make products because that’s where the profit margins are highest.